Literature DB >> 22884624

Antagonism of L-type Ca(v) channels with nifedipine differentially affects performance of wildtype and NK1R-/- mice in the 5-Choice Serial Reaction-Time Task.

Julia A Dudley1, Ruth K Weir, Ting C Yan, Ewelina M Grabowska, Ashley J Grimmé, Susana Amini, David N Stephens, Stephen P Hunt, S Clare Stanford.   

Abstract

Mice with functional ablation of the substance P-preferring receptor gene ('Nk1r' in mice ('NK1R-/-'), 'TACR1' in humans) display deficits in cognitive performance that resemble those seen in patients with Attention Deficit Hyperactivity Disorder (ADHD): namely, inattentiveness, impulsivity and perseveration. A recent report suggested that the L-type Ca(v) channel blocker, nifedipine, can ameliorate behavioral abnormalities of this type in humans. In light of evidence that NK1R antagonists modulate the opening of these L-type channels, we investigated whether nifedipine modifies %premature responses (impulsivity), perseveration or %omissions (inattentiveness) in the 5-Choice Serial Reaction-Time Task (5-CSRTT) and whether the response differs in NK1R-/- and wildtype mice. %Premature responses and perseveration were reduced in both genotypes, although wildtype mice were more sensitive to the effects of nifedipine than NK1R-/- mice. By contrast, nifedipine greatly increased %omissions but, again, was more potent in wildtypes. %Accuracy and locomotor activity were unaffected in either genotype. We infer that behavior of mice in the 5-CSRTT depends on the regulation of striato-cortical networks by L-type Ca(v) channels and NK1R. We further suggest that disruption of NK1R signaling in patients with ADHD, especially those with polymorphisms of the TACR1 gene, could lead to compensatory changes in the activity of L-type channels that underlie or exacerbate their problems. This article is part of a Special Issue entitled 'Cognitive Enhancers'.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22884624     DOI: 10.1016/j.neuropharm.2012.06.056

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  10 in total

1.  Impact on Cortical Function of Cocaine Abuse Co-Occurring with HIV.

Authors:  T Celeste Napier
Journal:  Neuropsychopharmacology       Date:  2017-01       Impact factor: 7.853

Review 2.  Exploring the Validity of Proposed Transgenic Animal Models of Attention-Deficit Hyperactivity Disorder (ADHD).

Authors:  June Bryan de la Peña; Irene Joy Dela Peña; Raly James Custodio; Chrislean Jun Botanas; Hee Jin Kim; Jae Hoon Cheong
Journal:  Mol Neurobiol       Date:  2017-05-22       Impact factor: 5.590

3.  Animal Models of ADHD?

Authors:  S Clare Stanford
Journal:  Curr Top Behav Neurosci       Date:  2022

4.  The angiotensin converting enzyme inhibitor, captopril, prevents the hyperactivity and impulsivity of neurokinin-1 receptor gene 'knockout' mice: sex differences and implications for the treatment of attention deficit hyperactivity disorder.

Authors:  Ashley J Porter; Katharine Pillidge; Ewelina M Grabowska; S Clare Stanford
Journal:  Eur Neuropsychopharmacol       Date:  2015-02-07       Impact factor: 4.600

5.  A lack of functional NK1 receptors explains most, but not all, abnormal behaviours of NK1R-/- mice(1).

Authors:  A J Porter; K Pillidge; Y C Tsai; J A Dudley; S P Hunt; S N Peirson; L A Brown; S C Stanford
Journal:  Genes Brain Behav       Date:  2015-02-01       Impact factor: 3.449

6.  Atomoxetine reduces hyperactive/impulsive behaviours in neurokinin-1 receptor 'knockout' mice.

Authors:  Katharine Pillidge; Ashley J Porter; Temis Vasili; David J Heal; S Clare Stanford
Journal:  Pharmacol Biochem Behav       Date:  2014-10-24       Impact factor: 3.533

7.  The Oxford study of Calcium channel Antagonism, Cognition, Mood instability and Sleep (OxCaMS): study protocol for a randomised controlled, experimental medicine study.

Authors:  Lauren Z Atkinson; Lucy Colbourne; Alexander Smith; Catherine H Harmer; Anna C Nobre; Jennifer Rendell; Helen Jones; Christopher Hinds; Arne Mould; Elizabeth M Tunbridge; Andrea Cipriani; John R Geddes; Kate E A Saunders; Paul J Harrison
Journal:  Trials       Date:  2019-02-12       Impact factor: 2.279

8.  Differences in the performance of NK1R-/- ('knockout') and wildtype mice in the 5‑Choice Continuous Performance Test.

Authors:  Ashley J Porter; Katharine Pillidge; S Clare Stanford; Jared W Young
Journal:  Behav Brain Res       Date:  2015-11-11       Impact factor: 3.332

9.  The behavioural response of mice lacking NK₁ receptors to guanfacine resembles its clinical profile in treatment of ADHD.

Authors:  Katharine Pillidge; Ashley J Porter; Julia A Dudley; Yuan-Chen Tsai; David J Heal; S Clare Stanford
Journal:  Br J Pharmacol       Date:  2014-10       Impact factor: 8.739

10.  Perseveration by NK1R-/- ('knockout') mice is blunted by doses of methylphenidate that affect neither other aspects of their cognitive performance nor the behaviour of wild-type mice in the 5-Choice Continuous Performance Test.

Authors:  Katharine Pillidge; Ashley J Porter; Jared W Young; S Clare Stanford
Journal:  J Psychopharmacol       Date:  2016-04-19       Impact factor: 4.153

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.